Pyxis Oncology (PYXS) said Tuesday it will present new preclinical data from its phase 1 study of micvotabart pelidotin, antibody-drug conjugate to treat recurrent and metastatic head and neck squamous cell carcinoma, at the American Association for Cancer Research Meeting in Chicago in April.

In phase 1 trial, the drug showed monotherapy effect on multiple tumor types with significant tumor regression, according to the company. It has begun the part 2 monotherapy expansion cohorts of the ongoing Phase 1 to assess Micvo in second-line and third-line recurrent and metastatic head and neck squamous cell carcinoma patients who have received prior platinum and PD-1 inhibitor therapy and those who received prior EGFRi and PD-1 inhibitor therapy.

The company added that preliminary data for patients who received prior platinum and PD-1 inhibitor therapy are expected in H2. Preliminary data from those who received prior EGFRi and PD-1 inhibitor therapy are expected in H1 2026.

The company said it also started a phase 1/2 combination study of Micvo and Merck's anti-PD-1 therapy, Keytruda, in patients with R/M HNSCC and other solid tumors to identify the recommended Phase 2 dose by mid-2025.